Alexium International Group Limited · ASX:AJX
Alexium International — Q3 FY2024 Earnings Presentation
15 slides from Alexium International's earnings presentation, Apr 26, 2024
Slide 1: Investors' Webinar FY2024 Q3 Quarterly Activities Report
For personal use only ALEXIUM INTERNATIONAL GROUP LIMITED Investors’ Webinar FY2024 Q3 Quarterly Activities Report 26 April 2024 ABN 91 064 820 408 PRESENTED IN US DOLLARS
Slide 2: Introduction
For personal use only INTRODUCTION
Slide 3: FY24 Q3 Focus
FY24 Q3 FOCUS For personal use only Focus shifting to business and product New opportunities in flame-resistant development activities adjacent to (FR) technologies in bedding due to thermal regulation in bedding in North changes in the regulatory environment America “Alexium’s value to customers is
Slide 4: FY24 Strategic Objectives Update
FY24 Strategic Objectives Update Team: Build out direct sales and business development. Status: Two new sales executives joined the team in late Q3 and early Q4 to increase business development activities For personal use only globally across all AJX product markets. AJX has retained a former seni
Slide 5: FY24 Strategic Objectives Update (cont.)
FY24 Strategic Objectives Update (cont.) Operations: Secure the Company’s supply chain to ensure resiliency. Status: Over the last year, Alexium has added a For personal use only textile engineer to lead the qualification of additional suppliers in textile finishing to increase quality and reduce
Slide 6: FY24 Q3 Highlights & Focus Priorities
In Q3 FY24 we made significant progress against these FY24 objectives, including: Achieving year-on-year revenue growth in our core focus areas: For personal use only PCM – Maintain and Grow North American share, Penetrate Global Markets o Three new BioCool® product placements in OEM foam mattress
Slide 7: FY24 Q3 Highlights & Focus Priorities (cont.)
● DelCool fabric sales growth in bedding (cont) o Mattress: Product development underway for inclusion in a luxury mattress launch by a major bedding brand. If this development proves successful, the target launch would be for FY26 and could result in a significant increase in Group revenues with a
Slide 8: FY24 Q3 Highlights & Focus Priorities: FR Nyco and Eclipsys
● Progressing FR Nyco for military and commercialising Eclipsys® fabric for tactical gear Flame Resistant (FR) Technologies: ○ Alexiflam® chemistry – FR NyCo: After passing the Pyroman burn test at NC State University, product development work has continued to enhance the aesthetics of the fabric ta
Slide 9: FY24 Q3 Highlights & Focus Priorities (cont.)
Commercialising PCM, Eclipsys® fabric, and FR into new markets (e.g., shoes, cold chain, workwear): Eclipsys® fabric for footwear o Successful internal testing concluded on an athletic shoe For personal use only application. Results were presented to a prospective industry- leading customer in Q3.
Slide 10: FY24 Q3 Highlights & Focus Priorities (cont.)
Commercialising PCM, Eclipsys® fabric, and FR into new markets (e.g., shoes, cold chain, workwear): Alexiflam® products for workwear o Alexium is working on improvements to the wash durability of For personal use only Alexiflam® chemistry incorporated into Nylon/Cotton blended fabric to meet the r
Slide 11: Expansion of Supply Agreements with Major Customers
SUPPLY AGREEMENTS WITH MAJOR CUSTOMERS: We worked with multiple larger customers to move away from spot purchasing and specific program buying to long-term product supply agreements that define pricing, supply capabilities and Alexium’s analytical support. • Supply Agreement - BekaertDeslee NV - Q2
Slide 12: Expansion of Commercial Strategies
EXPANSION OF THE BUSINESS TEAM: The Company laid out plans to restructure the sales and marketing team in Q2 FY24, then began recruiting For personal use only sales/business development professionals in Q3. The Company identified and hired two new sales professionals who joined the Alexium team in Q
Slide 13: Capital Raise, Refinancing and Bridge Loan
For personal use only In the previous quarter, the Company announced its intentions to enter into a capital raise and refinancing transaction (“Transaction”), pending shareholder Capital Raise, approval (see the ASX announcement on 27 December 2023). The capital raise will provide a minimum equity o
Slide 14: Q3 FY2024 Cash Flow
Alexium continues to apply a disciplined approach of prioritising short-term revenue opportunities while advancing secondary new business focus areas to ensure medium to long-term growth objectives are met. The Company For personal use only has been applying the same level of discipline to managing
Slide 15: Q3 FY2024 Cash Flow Commentary
Operating activity outflows (refer to Appendix 4C Item 1.2) primarily consist of raw material purchases, manufacturing costs, staffing costs, and corporate/administrative costs. The Company experienced a quarter-over- For personal use only quarter increase in raw material purchases and production-re
Alexium International Group — Q3 FY2024 Earnings Presentation on 6ix